Edesa Biotech Inc. (EDSA), a clinical-stage biopharmaceutical company, on Thursday reported entering a Private Investment in Public Equity (PIPE) placement with healthcare-focused investors and the company's Chief Executive Officer (CEO).
Shares increased by over 8% on Thursday.
The company plans to issue 729,241 shares in the PIPE, priced at $4.69 per share for general investors, and $5.21 per share for the CEO.
Gross proceeds are estimated at $3.5 million. The company plans to utilize proceeds in developing its vitiligo program, and for the advancement of Paridiprubart, a potential treatment for advanced respiratory stress syndrome.
The PIPE placement is expected to close on June 15, 2026.
EDSA closed Thursday at $5.65, up 8.45%. In the pre-market, shares are trading at $5.70, up 0.88%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.